ATT-11T
Pre-clinical- Indications
- Stomach cancer, Solid tumors
Company intelligence / Profile preview
Aposense Ltd.
Petah Tikva, HaMerkaz, Israelinterna.bio ↗
- Ownership
- Public · APOS
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Aposense has developed a patented technology to target apoptotic cells in vivo using rationally designed small molecules. Its lead imaging agent ([18F]-ML10) reached Phase II clinical trials for early detection of tumor response to therapy. The company’s therapeutic pipeline includes ATT‑11T, a Topoisomerase I inhibitor conjugate for solid tumors currently at the preclinical stage. The company also collaborates on siRNA brain delivery platforms and has several academic and industry partnerships.[1][2][4][6]
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small moleculessiRNA (genetic drugs)Diagnostic radiopharmaceuticals[2][4][6]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Teva PharmaceuticalsIBA S.A.Sigma-AldrichBioasis Technologies Inc.[1][2]
04
Financials
- Market cap
- $74.1B
- Total revenue
- $11.2B
- Enterprise value
- $61B
Beyond the preview
Go deeper on Aposense Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aposense Ltd..